FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Brown Dennis M 2. Issuer Name and Ticker or Trading Symbol Kintara Therapeutics, Inc. [ KTRA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)         (First)         (Middle)
12707 HIGH BLUFF DR., SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)
11/12/2019
(Street)
SAN DIEGO, CA 92130
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
11/14/2019 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to Buy)  $0.735  11/12/2019    A     250000       (1) 11/12/2029  Common Stock  250000  $0  250000  D   

Explanation of Responses:
(1)  This amendment is being filed to update the vesting schedule of the option award made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vested on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Brown Dennis M
12707 HIGH BLUFF DR., SUITE 200
SAN DIEGO, CA 92130


Chief Scientific Officer

Signatures
/s/ Anthony Scott Praill, attorney-in-fact for Dennis M. Brown 9/24/2020
**Signature of Reporting Person Date
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Kintara Therapeutics Charts.
Kintara Therapeutics (NASDAQ:KTRA)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Kintara Therapeutics Charts.